Marc Samuels Discusses Key Insights on Cell and Gene from Meeting on the Mesa
Marc Samuels, JD, MPH
October 24, 2023
ADVI expert Marc Samuels attended the 2023 Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa and chaired two important sessions:
- Fireside Chat: Headwinds and Tailwinds Facing Patients, Providers, and Producers
Chair: Marc Samuels, CEO, ADVI Health
Speakers: Ellen Lukens, CEO, Deputy Director, Center for Medicare & Medicaid Innovation, CMS Innovation Center - Medicare – A Look on the Cell Therapy Landscape
Chair: Marc Samuels, CEO, ADVI Health
Speakers: Stephanie Farnia, Principal, Nimitt Consulting
Marianne Hamilton Lopez, Ph.D., Senior Research Director, Biomedical
Innovation, Duke-Margolis Center for Health Policy
Laura Okpala, Senior Director, Policy, Gilead Sciences
Keren Shani, Executive Director, Cell & Gene Therapy, Trinity
Hear from Marc, now following the event, as he discusses his key takeaways including the future of regenerative medicine, Medicare and Medicaid innovation, CAR T-cell therapy, and the evolving landscape of healthcare policies. He will explore vital topics such as reimbursement, regulatory changes, and the role of commercial payers in shaping the future of healthcare.
Learn More
Stay ahead of the curve. Get in touch today to gain expert insights on Cell and Gene and the evolving healthcare landscape.
Marc Samuels, JD, MPH
Chief Executive Officer
CEO insights
Related articles
Real analysis from people who’ve been there
March Is Colorectal Cancer Awareness Month: Why CMS’s Proposed NCD 210.3 Update Could Accelerate Patient‑Centered Screening Access
Colorectal cancer (CRC) screening saves lives, but only when patients are able to access care in a way that meets …
The 2026 Rare Disease Reality
Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …
Marc Samuels, JD, MPH
February 26, 2026
Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care
CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …
Alicia Silver, MPP
November 21, 2025
ADVI Research: Medicare Beneficiaries with Multiple Administrations of CAR-T
ADVI Health Strategic Analytics, Value and Economics (SAVEs) chief data scientist, Pete Kardel, and the team presented four poster presentations …
Peter Kardel, MA
May 21, 2024
What are We Excited to Bring to ADVI Clients in 2024?
As the first quarter of 2024 is coming to a close, we wrap up our 2024 ADVI Health Predictions series …
ADVI Instant: Colorado PDAB Votes to Establish an Upper Payment Limit for Enbrel
On February 23, 2024, the Colorado Prescription Drug Affordability Board (PDAB) voted unanimously to move forward with establishing an upper …
ADVI Instant: CMS Releases Draft Part Two Guidance for the MPPP program
On February 15, the Centers for Medicare and Medicaid Services (CMS) released the Draft Part Two Guidance on the Medicare …
Brenna Raines, MHA
February 22, 2024
Top 5 Questions Clients Should be Asking in 2024
We are a month into 2024, and our clients are consistently seeking unique ways to improve access to care and …
Marc Samuels, JD, MPH
February 9, 2024
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.